Invega Sustenna

Discussion in 'Janssen' started by Anonymous, Jul 14, 2009 at 12:29 PM.

  1. Anonymous

    Anonymous Guest

    Has anyone hurd of anything about the new Invega shot coming out called Invega Sustenna.
     
  2. Anonymous

    Anonymous Guest

    Yes, being launched in Q4 2010
     
  3. Anonymous

    Anonymous Guest

    yea right.....try q4 2009!!
     
  4. Anonymous

    Anonymous Guest

    The pdufa is 8/4/09
     
  5. Anonymous

    Anonymous Guest

    Re: Invega Sustenna (paliperidone palmitate)

    Attribute**RISPERDAL®CONSTA®***INVEGA®SUSTENNA™Robust efficacy profile Favorable tolerability profile, Administration every 4 weeks, No oral supplementation, Multiple administration sites, Small gauge needle, Storage and preparation (no reconstitution or refrigeration necessary)
     
  6. Anonymous

    Anonymous Guest

    This will be led by a team led by Lynda Benton, who did a great job with both Risperdal oral and Concerta. Look for some really good things
     
  7. Anonymous

    Anonymous Guest

    A quick review is:

    First study with pali did not separate from Ris Consta = dose was too low.

    Second study at a higher dose looks very good vs. Ris Consta.

    Advantages vs. Consta:

    works from day one
    no titration from oral drugs
    side effects were less than consta
    efficacy similar, but once a month injection vs. every 2 weeks
    no refrigeration
    no more beads (micro spheres)
    smaller needle
    works gluteal or deltoid

    PDUFA 8/3/2009
     
  8. Anonymous

    Anonymous Guest

    3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.
     
  9. Anonymous

    Anonymous Guest

    INVEGA SUSTENNA WAS APPROVED ON FRIDAY (July 31).
     
  10. Anonymous

    Anonymous Guest

    I have never been more proud to be a part of Janssen! Invega Sustenna is a revolutionary product that will change the landscape of pyschiatric medicine. I am so excited to go out and sell this great product.
     
  11. Anonymous

    Anonymous Guest

    I agree

    How are the patients responding to Invega Sustenna?
    Any bad side effects happening?
    Any complaints about cost?
     
  12. Anonymous

    Anonymous Guest

    Saphris will dominate the APS market, Invega and Sustena are done.
     
  13. Anonymous

    Anonymous Guest

    The four week formulation of INVEGA SUSTENNA (PALIPERIDONE PALMITATE) will replace the two week formulation of RISPERDAL CONSTA. INVEGA SUSTENNA works from day one and oral pills do not have to be taken for 3 weeks when starting like RISPERDAL CONSTA does. Invega is the follow up medication to Risperdal so the medication is generally better. Two injections shots have to be given the first week of SUSTENNA. Then once every 4 weeks.

    Initiate INVEGA SUSTENNA with a dose of 234 mg on treatment day 1 and
    156 mg one week later, both administered in the deltoid muscle. The recommended
    monthly maintenance dose is 117 mg


    Prefilled syringes containing 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg paliperidone
    palmitate.
     
  14. Anonymous

    Anonymous Guest

    and first month cost = $2,500.00? :( unbelievable!
     
  15. Anonymous

    Anonymous Guest

    What's the cost of the monthly maintenance dose 117 mg?
     
  16. Anonymous

    Anonymous Guest

    That's WITH the loading dose: 2 injections the first week so it works within 4 to 8 days! Then q30days.
     
  17. Anonymous

    Anonymous Guest

    Don't get too excited, it's still invega. Could be once a year, docs don't like the drug. Invega share shows it. The convenience stuff is over played. Will give Haldol dec a run, but expect a lackluster launch. $2500 will go over well with payers.
     
  18. Anonymous

    Anonymous Guest

    LOL! Obviously you're a PCP rep. Oral Invega didn't take off because it was like 6th to market. The drug works perfectly fine. Also, ask payers how much it costs to pay for one week of inpatient care..........I think it's waaay more then $2500. Oh, by the way, the company has already distributed more then they projected to wholesalers/pharmacies based on demand sooooooo, I think you can expect a better then lackluster launch. LOL!
     
  19. Anonymous

    Anonymous Guest

    Do you really believe hospitals and county formularies think that far ahead? They only care about today's out-the-door-cost, not about long term inpatient costs. Do you really think hospital pharmacies are not going to be concerned about blowing $2,500.00 and praying the patient eventually comes back? Don't you understand that most hospitals have a monthly cap for patients and $2,500 blows are through this? This launch is going to be embarrassing. You can bank on it!
     
  20. Anonymous

    Anonymous Guest

    why are reps out there talking about this drug when they don't know crap about it
    what a waste of a providers time when your company has not even educated you on the product
    wonder what the fda would think about that? maybe i should be a whistleblower
     

Share This Page